Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.

Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the Cεmx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.

Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the Cεmx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.

This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.

Disclosed herein are GABAA positive allosteric modulators for the treatment of pruritic conditions and dermatitis. Also disclosed herein are formulations comprising the GABAA positive allosteric modulators.

Disclosed herein are GABAA positive allosteric modulators for the treatment of pruritic conditions and dermatitis. Also disclosed herein are formulations comprising the GABAA positive allosteric modulators.

The current invention is based on the determination that a S1P receptor modulator compound of formula (I):

##STR00001##

decreases the heart rate of a subject to which it is administered by about 5 beats/min or less daily, or about 4 beats/min or less daily, or about 3 beats/min or less daily, or about 2 beats/min or less daily, wherein the S1P receptor modulator is administered at an initial daily dosage which is substantially the same as the standard daily therapeutic dosage.

The current invention is based on the determination that a S1P receptor modulator compound of formula (I):

##STR00001##

decreases the heart rate of a subject to which it is administered by about 5 beats/min or less daily, or about 4 beats/min or less daily, or about 3 beats/min or less daily, or about 2 beats/min or less daily, wherein the S1P receptor modulator is administered at an initial daily dosage which is substantially the same as the standard daily therapeutic dosage.

The present invention relates to methods for treating prurigo nodularis with anti-pruritic compositions, wherein the method provides a therapeutic effect in a patient.

The present invention relates to methods for treating prurigo nodularis with anti-pruritic compositions, wherein the method provides a therapeutic effect in a patient.